Galapagos’ bowel drug misses the mark in Phase II

Damian Garde

Belgian biotech is shutting down an ulcerative colitis program after its top prospect failed to make a difference in a II trial, putting off plans for late-stage development as the company weighs whether to move forward in another disease.

FierceBiotech News

Share This Post

Related Articles

Leave a Reply

© 2019 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS